Fulcrum Therapeutics, Inc.
FULC
$7.63
-$0.02-0.26%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | 0.00 | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | 0.00 | -- |
| Cost of Revenue | 14.30M | 12.99M | 13.40M | 11.71M | 14.64M |
| Gross Profit | -14.30M | -12.99M | -13.40M | -11.71M | -14.64M |
| SG&A Expenses | 7.56M | 6.83M | 7.00M | 7.72M | 8.42M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.86M | 19.82M | 20.40M | 19.43M | 23.06M |
| Operating Income | -21.86M | -19.82M | -20.40M | -19.43M | -23.06M |
| Income Before Tax | -19.60M | -17.30M | -17.66M | -16.57M | -21.70M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -19.60M | -17.30M | -17.66M | -16.57M | -21.70M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.60M | -17.30M | -17.66M | -16.57M | -21.70M |
| EBIT | -21.86M | -19.82M | -20.40M | -19.43M | -23.06M |
| EBITDA | -21.51M | -19.47M | -20.05M | -19.06M | -22.69M |
| EPS Basic | -0.31 | -0.28 | -0.28 | -0.31 | -0.35 |
| Normalized Basic EPS | -0.20 | -0.17 | -0.18 | -0.19 | -0.20 |
| EPS Diluted | -0.31 | -0.28 | -0.28 | -0.31 | -0.35 |
| Normalized Diluted EPS | -0.20 | -0.17 | -0.18 | -0.19 | -0.20 |
| Average Basic Shares Outstanding | 62.60M | 62.54M | 62.48M | 53.95M | 62.41M |
| Average Diluted Shares Outstanding | 62.60M | 62.54M | 62.48M | 53.95M | 62.41M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |